Drug Trial Radar · NCT05004675
Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
166
Actual
Start
Jun 20, 2022
Primary completion
May 30, 2024
Study completion Oct 15, 2024
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug therapy
Conditions
- Hypercholesterolemia
- Atherosclerotic Ischemic Disease
Interventions
lerodalcibepBiological
300 mg
InclisiranDrug
284 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C changeTime frame: Day 270
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
CHU de Nantes - Hôpital Nord Laennec
Nantes, Cedex 01, France
Hopitaux de Marseille
Marseille, Cedex 05, France
Universitätsklinikum Heidelberg - Medizinische Klinik
Heidelberg, Germany
The Lipid Clinic (Oslo University Hospital)
Oslo, Nydalen, Norway
Hospital Universitario Miguel Servet
Zaragoza, Spain
Oak Tree Surgery and Pensilva Health Centre
Liskeard, Cornwall, United Kingdom
Ashton Medical Group
Ashton-under-Lyne, Lancashire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.